I am a
Home I AM A Search Login

Papers of the Week

Papers: 21 Nov 2020 - 27 Nov 2020

Human Studies, Pharmacology/Drug Development

2020 Nov 26

Pain Manag

Quality of life and functional outcomes with tapentadol prolonged release in chronic musculoskeletal pain: analysis.


Margarit Ferri C, Natoli S, Sanz-Ayan P, Magni A, Guerrero C, Lara-Solares A, Liedgens H, Thömmes G, Karra R
Pain Manag. 2020 Nov 26.
PMID: 33241725.


To investigate quality of life (QOL) and functionality changes in chronic pain during tapentadol prolonged release (PR) treatment. analysis of data from three Phase III trials in patients with osteoarthritis knee pain or low back pain. QOL and functionality changes were assessed by SF-36 scores. All SF-36 subdomain scores improved progressively to week 3 of tapentadol titration and were sustained during 12-week maintenance treatment. Improvements in SF-36 scores were similar between tapentadol dose groups (e.g., 200 to <300 mg vs ≥500 mg), with no greater effect from higher doses. QOL and functionality improvements were consistently greater with tapentadol PR than oxycodone controlled release. Tapentadol PR provides consistent, clinically relevant improvements in QOL and functionality in chronic pain.